JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312374

Alexa Fluor® 568 Anti-LMO2 抗体 [SP51] - N-terminal

Alexa Fluor® 568 Anti-LMO2 antibody [SP51] - N-terminal

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal LMO2 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

RBTN2, RBTNL1, RHOM2, TTG2, LMO2, Rhombotin-2, Cysteine-rich protein TTG-2, LIM domain only protein 2, T-cell translocation protein 2, LMO-2

関連する標識済み抗体及び組成の異なる製品 (9)

  • Unconjugated

    Anti-LMO2 antibody [SP51] - N-terminal

  • 578 PE

    PE Anti-LMO2 antibody [SP51] (N-terminal)

  • HRP

    HRP Anti-LMO2 antibody [SP51] (N-terminal)

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-LMO2 antibody [SP51] - N-terminal

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-LMO2 antibody [SP51] - N-terminal

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-LMO2 antibody [SP51] - N-terminal

  • 660 APC

    APC Anti-LMO2 antibody [SP51] (N-terminal)

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-LMO2 antibody [SP51] - N-terminal

  • Carrier free

    Anti-LMO2 antibody [SP51] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

SP51

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column
style
left-column

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

LMO2 also known as LIM Domain Only 2 is a transcription factor with a molecular weight of approximately 24 kDa. It contains two LIM domains which enable protein-protein interactions. LMO2 expression is mostly found in hematopoietic tissues and the vascular endothelium. This protein does not directly bind DNA but forms complexes with other proteins to exert its regulatory roles.
Biological function summary

This transcription factor is important in hematopoiesis and angiogenesis. LMO2 forms multiprotein complexes that include TAL1 GATA1 and E47 which are necessary for the transcriptional activation of genes involved in blood cell differentiation and formation. Its role in angiogenesis involves participating in the transcriptional regulation of genes essential for blood vessel formation.

Pathways

LMO2 plays a significant role in the development of the hematopoietic system and vascular network. It is part of the TAL1-LMO2-LDB1 transcriptional complex within the hematopoietic transcriptional network which includes other key proteins like GATA1 and E47. These pathways ensure proper development and differentiation of various blood cell lineages and endothelial cells.

LMO2 has a known association with T-cell acute lymphoblastic leukemia (T-ALL) and some other hematological malignancies. Abnormal expression of LMO2 can lead to oncogenic transformation in hematopoietic cells. Within these disease contexts LMO2 interacts with proteins like TAL1 and LDB1 contributing to leukemogenic processes. Understanding its role helps in the development of therapeutic strategies targeting these pathways.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state.
See full target information LMO2
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column

関連製品

Select an associated product type
Alternative Version
Primary Antibodies

AB240267

Anti-LMO2 antibody [SP51] - BSA and Azide free

primary-antibodies

lmo2-antibody-sp51-bsa-and-azide-free-ab240267

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com